Better tolerance of preservative-free latanoprost compared to preserved glaucoma eye drops: the 12-month real-life FREE study

Mario A Economou1 Anterior Segment Department, St Erik’s Eye Hospital, Karolinska Institute, Stockholm, Sweden, [email protected]Correspondence[email protected]

Helene Kolstad Laukeland2 Department of Ophthalmology, University Hospital, Trondheim, Norway;3 Department of Laboratory Medicine, Norwegian University of Science and Technology, Trondheim, Norway

Iwona Grabska-Liberek4 Department of Ophthalmology, Ophthalmology Clinic Postgraduate Centre of Medical Education, Warszawa, Poland

Jean-François Rouland5 Department of Ophtalmology, Claude Huriez Hospital, University Hospital, Lille, France

Pages 2399-2407 | Published online: 26 Nov 2018

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

van der ValkRWebersCASchoutenJSZeegersMPHendrikseFPrinsMHIntraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trialsOphthalmology200511271177118515921747
PubMed Web of Science ®Google Scholar
AriasASchargelKUssaFCanutMIRoblesAYSánchezBMPatient persistence with first-line antiglaucomatous monotherapyClin Ophthalmol2010426126720463793
PubMedGoogle Scholar
EyawoONachegaJLefebvrePEfficacy and safety of prostaglandin analogues in patients with predominantly primary open-angle glaucoma or ocular hypertension: a meta-analysisClin Ophthalmol2009344745619684868
PubMedGoogle Scholar
HonrubiaFGarcía-SánchezJPoloVde la CasaJMSotoJConjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomised clinical trialsBr J Ophthalmol200993331632119019922
PubMed Web of Science ®Google Scholar
AlmALatanoprost in the treatment of glaucomaClin Ophthalmol201481967198525328381
PubMedGoogle Scholar
European Glaucoma Society Terminology and Guidelines for Glaucoma, 4th Edition – Chapter 2: Classification and terminology Supported by the EGS Foundation: Part 1: Foreword; Introduction; Glossary; Chapter 2 Classification and TerminologyBr J Ophthalmol201710157312728424171
PubMed Web of Science ®Google Scholar
BaudouinCLabbéALiangHPaulyABrignole-BaudouinFPreservatives in eyedrops: the good, the bad and the uglyProg Retin Eye Res201029431233420302969
PubMed Web of Science ®Google Scholar
JaenenNBaudouinCPouliquenPManniGFigueiredoAZeyenTOcular symptoms and signs with preserved and preservative-free glaucoma medicationsEur J Ophthalmol200717334134917534814
PubMed Web of Science ®Google Scholar
RoulandJFTraversoCEStalmansIT2345 Study GroupEfficacy and safety of preservative-free latanoprost eyedrops, compared with BAK-preserved latanoprost in patients with ocular hypertension or glaucomaBr J Ophthalmol201397219620023203707
PubMed Web of Science ®Google Scholar
FeldmanRMConjunctival hyperemia and the use of topical prostaglandins in glaucoma and ocular hypertensionJ Ocul Pharmacol Ther2003191233512648301
PubMed Web of Science ®Google Scholar
JonesLDownieLEKorbDTFOS DEWS II Management and Therapy ReportOcul Surf201715357562828736343
PubMed Web of Science ®Google Scholar
NordmannJPAuzanneauNRicardSBerdeauxGVision related quality of life and topical glaucoma treatment side effectsHealth Qual Life Outcomes200317514667241
PubMedGoogle Scholar
ZimmermanTJHahnSRGelbLTanHKimEEThe impact of ocular adverse effects in patients treated with topical prostaglandin analogs: changes in prescription patterns and patient persistenceJ Ocul Pharmacol Ther200925214515219284321
PubMed Web of Science ®Google Scholar
AptelFChoudhryRStalmansIPreservative-free versus preserved latanoprost eye drops in patients with open-angle glaucoma or ocular hypertensionCurr Med Res Opin20163281457146327310103
PubMed Web of Science ®Google Scholar
CucheratMStalmansIRoulandJFRelative efficacy and safety of preservative-free latanoprost (T2345) for the treatment of open-angle glaucoma and ocular hypertension: an adjusted indirect comparison meta-analysis of randomized clinical trialsJ Glaucoma2014231e69e7523881267
PubMed Web of Science ®Google Scholar
IEAInternational Epidemiological Association: Good Epidemiological Practice (GEP), IEA Guidelines for properconduct in epidemiological research, November 2007 Available from: http://ieaweb.org/good-epidemiological-practice-gep/Accessed March 7, 2018
Google Scholar
CraigJPNicholsKKAkpekEKTFOS DEWS II Definition and Classification ReportOcul Surf201715327628328736335
PubMed Web of Science ®Google Scholar
LemijHGHoevenaarsJGvander Windt CBaudouinCPatient satisfaction with glaucoma therapy: reality or myth?Clin Ophthalmol2015978579325999687
PubMed Web of Science ®Google Scholar
MuñozNegrete FJLemijHGErbCSwitching to preservative-free latanoprost: impact on tolerability and patient satisfactionClin Ophthalmol20171155756628356710
PubMedGoogle Scholar
Martinez-de-la-CasaJMPerez-BartolomeFUrcelayETear cytokine profile of glaucoma patients treated with preservative-free or preserved latanoprostOcul Surf201715472372928342814
PubMed Web of Science ®Google Scholar
PisellaPJPouliquenPBaudouinCPrevalence of ocular symptoms and signs with preserved and preservative free glaucoma medicationBr J Ophthalmol200286441842311914211
PubMed Web of Science ®Google Scholar
WilsonWSDuncanAJJayJLEffect of benzalkonium chloride on the stability of the precorneal tear film in rabbit and manBr J Ophthalmol197559116676691203224
PubMed Web of Science ®Google Scholar
JeeDParkSHKimMSKimECAntioxidant and inflammatory cytokine in tears of patients with dry eye syndrome treated with preservative-free versus preserved eye dropsInvest Ophthalmol Vis Sci20145585081508924994869
PubMed Web of Science ®Google Scholar
PaulyARoubeixCLiangHBrignole-BaudouinFBaudouinCIn vitro and in vivo comparative toxicological study of a new preservative-free latanoprost formulationInvest Ophthalmol Vis Sci201253138172818023150620
PubMed Web of Science ®Google Scholar
Newman-CaseyPABlachleyTLeePPHeislerMFarrisKBSteinJDPatterns of Glaucoma Medication Adherence over Four Years of Follow-UpOphthalmology2015122102010202126319441
PubMed Web of Science ®Google Scholar
ThygesenJGlaucoma therapy: preservative-free for all?Clin Ophthalmol20181270771729713138
PubMed Web of Science ®Google Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Better tolerance of preservative-free latanoprost compared to preserved glaucoma eye drops: the 12-month real-life FREE study

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Better tolerance of preservative-free latanoprost compared to preserved glaucoma eye drops: the 12-month real-life FREE study

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date